Contribute Try STAT+ Today

I have a dream that one day all public information and all software will be free, transparent, and open source, and all people will have the skills to benefit from it. We are not living in my dream world yet. But here at STAT, we’re trying to do our part to open up a little more data stored in government databases.

Our first major project after we launched was a deep data-intensive dive into clinical trials compliance. In December 2015, we published “Failure to Report,” an investigation of the reporting of human study results to by government, academic, and industry scientists. We found flagrant violations of federal law and non-existent enforcement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.